Medicare Group Q.P.S.C.

INTERIM CONDENSED FINANCIAL STATEMENTS

FOR THE NINE-MONTH PERIOD ENDED 30 SEPTEMBER 2023

INTERIM STATEMENT OF FINANCIAL POSITION

At 30 September 2023

	Notes	30 September 2023 (Unaudited) QR	31 December 2022 (Audited) QR
ASSETS Non-current assets Property and equipment Investment properties Right-of-use assets Investments at fair value through other comprehensive income	4	1,047,211,257 26,233,810 35,829,927 66,821,220	1,032,712,543 26,233,810 37,592,055 69,730,395
		1,176,096,214	_1,166,268,803
Current assets Inventories Accounts receivable and prepayments Cash and bank balances	5	30,763,226 126,011,875 15,253,157	30,586,104 118,063,533 42,150,235
		172,028,258	190,799,872
Total assets		1,348,124,472	1,357,068,675
EQUITY AND LIABILITIES Equity Share capital Legal reserve Fair value reserve Revaluation reserve Retained earnings		281,441,000 116,010,669 15,456,276 546,413,693 54,478,997	281,441,000 116,010,669 18,365,451 549,025,726 75,356,136
Total equity		1,013,800,635	1,040,198,982
Non-current liabilities Bank facilities Lease liabilities Employees' end of service benefits	,	69,973,667 39,818,491 79,732,366 189,524,524	54,396,528 40,692,837 77,292,252 172,381,617
Current liabilities Accounts payable and accruals Bank facilities Lease liabilities		116,716,153 26,106,978 1,976,182	118,503,116 24,043,006 1,941,954
		144,799,313	144.488.076
Total liabilities	72	334,323,837	316,869,693
Total equity and liabilities		1,348,124,472	1,357,068,675

These interim condensed financial statements of the Company for the nine months ended 30 September 2023 were authorized for issue in accordance with resolution of the Board of Directors on 23 October 2023.

Abdul-Basit Ahmed Al-Shaibei

Vice Chairman & Managing Director

Khalid Mollammed Al-Emadi Chief Executive Officer

The attached notes 1 to 8 form part of these interim condensed financial statements.

Medicare Group Q.P.S.C.

INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the nine-month period ended 30 September 2023

		For the nine- ended 30 S	•
		2023	2022
		(Unaudited)	(Unaudited)
	Notes	QR	QR
Operating income		356,294,646	359,663,229
Operating costs	7	(226,484,834)	(224,200,049)
Gross profit		129,809,812	135,463,180
Income from deposits with Islamic Banks		459,239	288,759
Other income		5,523,791	5,825,074
General and administrative expenses	8	(69,852,957)	(69,897,042)
Depreciation of property and equipment		(12,510,253)	(11,974,324)
Amortisation of right-of-use assets		(1,762,128)	(2,030,633)
Finance costs		(1,278,413)	(1,634,629)
Net profit for the period		50,389,091	56,040,385
Other comprehensive income not to be reclassified to profit or loss in subsequent periods: Net (loss) / gain from investments at fair value through other			
comprehensive income		(2,909,175)	13,960,212
Other comprehensive (loss) / income for the period		(2,909,175)	13,960,212
Total comprehensive income for the period		47,479,916	70,000,597
Basic and diluted earnings per share (expressed in Qatari Riyals per share)		0.18	0.20

Medicare Group Q.P.S.C.

INTERIM STATEMENT OF CHANGES IN EQUITY
For the nine-month period ended 30 September 2023

	Share capital QR	Legal reserve QR	Fair value reserve QR	Revaluation reserve QR	Retained earnings QR	Total equity QR
Balance at 1 January 2022 Net profit for the period Other comprehensive income	281,441,000	108,094,188	14,944,967	552,508,436	72,964,472 56,040,385	1,029,953,063 56,040,385 13,960,212
Total comprehensive income		*	13,960,212		56,040,385	70,000,597
Dividends Transfer of depreciation of revalued assets	C (0)			(2,612,033)	(70,360,250) 2,612,033	(70,360,250)
Balance at 30 September 2022 (Unaudited)	281,441,000	108,094,188	28,905,179	549,896,403	61,256,640	1,029,593,410
Balance at 1 January 2023 Net profit for the period Other comprehensive loss	281,441,000	116,010,669	18,365,451 - (2,909,175)	549,025,726	75,356,136	1,040,198,982 50,389,091 (2,909,175)
Total comprehensive income		1 72	(2,909,175)		50,389,091	47,479,916
Dividends Transfer of depreciation of revalued assets		x 3	a a	(2,612,033)	(73,878,263) 2,612,033	(73,878,263)
Balance at 30 September 2023 (Unaudited)	281,441,000	116,010,669	15,456,276	546,413,693	54,478,997	1,013,800,635

Medicare Group Q.P.S.C.

INTERIM STATEMENT OF CASH FLOWS

For the nine-month period ended 30 September 2023

		For the nine- ended 30 S	
		2023	2022
		(Unaudited)	(Unaudited)
	Notes	QR	QR
OPERATING ACTIVITIES		~	2
Net profit for the period Adjustments for:		50,389,091	56,040,385
Depreciation of property and equipment	4	19,357,302	19,010,756
Amortisation of right-of-use assets		1,762,128	2,030,633
Provision for obsolete and slow - moving inventories		1,702,120	596,273
Provision for employees' end of service benefits		6,758,320	6,873,015
Finance costs		1,278,413	1,634,629
		1,2/0,413	
Gain on sale of property and equipment		(450.030)	(26,927)
Income from deposit with Islamic banks		(459,239)	(288,759)
Dividend income		(2,704,852)	(2,558,783)
Operating profit before working capital changes Working capital changes:		76,381,163	83,311,222
Inventories		(177,122)	(689,962)
Accounts receivable and prepayments		(3,349,737)	(15,565,037)
Accounts payable and accruals		(1,033,235)	(3,980,553)
A too dams payable and abortains		(1,033,233)	(5,500,555)
Cash generated from operations		71,821,069	63,075,670
Employees' end of service benefits paid		(4,318,206)	(4,295,966)
Contribution paid to the social and sports fund		(1,979,120)	(1,976,528)
Finance costs paid		(18,531)	(1,410)
Net cash flows from operating activities		65,505,212	56,801,766
INVESTING ACTIVITIES			
Additions to property and equipment	4	(33,856,016)	(30,382,485)
Advance payments towards capital projects	7	(4,598,605)	(18,775,720)
Proceeds from sale of property and equipment		(4,370,003)	26,927
Income received from deposit with Islamic banks		459,239	288,759
Dividend income received			2,558,783
Dividend income received		2,704,852	2,336,763
Net cash flows used in investing activities		(35,290,530)	(46,283,736)
FINANCING ACTIVITIES			
Cash dividends paid		(72,652,871)	(68,205,684)
Additional bank facilities obtained during the period		44,936,779	45,000,000
Payment of lease liabilities		(2,100,000)	(2,550,000)
Repayment of bank facilities		(27,295,668)	(19,986,821)
Net cash flows used in financing activities		(57,111,760)	(45,742,505)
NET DECREASE IN CASH AND CASH EQUIVALENTS		(26,897,078)	(35,224,475)
Cash and cash equivalents at the beginning of the period	4	42,150,235	52,247,073
CASH AND CASH EQUIVALENTS AT THE END OF THE			
PERIOD	71	15,253,157	17,022,598

NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS

At 30 September 2023

1 REPORTING ENTITY

Medicare Group Q.P.S.C. (formerly known as "Al Ahli Specialized Hospital Company Q.S.C.") is a Qatari Public Shareholding Company incorporated on 30 December 1996 under the Commercial Registration number 18895. The Company's main activity is the operation of a specialized hospital and promoting medical services in the State of Qatar. The Company's registered office address is at Ahmed Bin Ali Street, Wadi Al Sail, Doha, State of Qatar, P.O. Box 6401. The Company is listed on the Qatar Stock Exchange.

The Company provides medical services through Al Ahli Hospital located in Wadi Al Sail. The Company also operates a medical clinic center in Al Wakrah which has commenced its operations during February 2019.

The interim condensed financial statements of the Company for the nine months ended 30 September 2023 were authorized for issue in accordance with a resolution of the Board of Directors on 23 October 2023.

2 BASIS OF PREPARATION

The interim condensed financial statements of the Company are prepared in accordance with International Accounting Standard ("IAS") 34, Interim Financial Reporting. The financial statements are presented in Qatari Riyals ("QR"), which is the Company's functional and presentation currency. The interim condensed financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the annual financial statements of the Company for the year ended 31 December 2022. In addition, results for the nine month period ended 30 September 2023 are not necessarily indicative of the results that may be expected for the financial year ending 31 December 2023.

3 USES OF JUDGEMENTS AND ESTIMATES

In preparing these interim condensed financial statements, management has made judgements and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those described in the annual financial statements as at and for the year ended 31 December 2022.

4 PROPERTY AND EQUIPMENTS

	30 September 2023 (Unaudited) QR	31 December 2022 (Audited) QR
Net book value at 1 January Additions	1,032,712,543 33,856,016	1,013,292,628 45,247,907
Depreciation charge for the period/year	(19,357,302)	(25,827,992)
Disposal	-	(279,291)
Accumulated depreciation related to disposal	. <u> </u>	279,291
Net book value at end of the period/year	1,047,211,257	1,032,712,543

NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS

At 30 September 2023

5 ACCOUNTS RECEIVABLE AND PREPAYMENTS

	30 September 2023 (Unaudited) <u>Q</u> R	31 December 2022 (Audited) QR
Trade receivables	148,091,845	147,084,649
Advances to suppliers	35,662,860	31,645,555
Staff receivables	9,924,003	8,618,322
Prepaid expenses	5,855,330	3,386,993
Refundable deposits	1,717,701	1,714,000
Others	1,195,575	2,049,453
	202,447,314	194,498,972
Provision for expected credit losses on trade receivables	(76,435,439)	(76,435,439)
	126,011,875	118,063,533

6 CASH AND CASH EQUIVALENTS

Cash and cash equivalents comprise of the following:

	30 September	31 December
	2023	2022
	(Unaudited)	(Audited)
	QR	QR
Cash in hand	513,242	283,984
Cash at bank - current accounts	14,739,915	21,866,251
Cash at bank - short-term deposits	<u></u>	20,000,000
	15,253,157	42,150,235

7 OPERATING COSTS

	For the nine-n ended 30 S	4
	2023	2022
	(Unaudited)	(Unaudited)
	QR	QR
Staff costs	122,738,777	122,425,763
Medication and surgical costs	64,393,369	63,824,269
Doctors' charges	26,114,081	24,228,590
Depreciation of medical equipment	6,847,049	7,036,432
Utilities	2,902,685	2,626,048
Food costs	2,428,195	2,534,388
Fuel costs	1,060,678	924,173
Provision for slow moving inventories		600,386
	226,484,834	224,200,049

NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS

At 30 September 2023

8 GENERAL AND ADMINISTRATIVE EXPENSES

	For the nine-n ended 30 Sc	•
	2023	2022
	(Unaudited))	(Unaudited)
	QR	QR
Staff costs	40,667,865	43,097,593
Maintenance and repairs	6,970,000	6,079,084
Outsourced staff costs	4,285,466	4,248,340
IT development	3,120,618	2,655,645
Security and cleaning	2,908,966	2,651,205
Insurance	2,668,943	2,521,657
Board of Directors' remuneration	1,765,075	2,021,907
Telephone and fax	1,758,627	1,905,729
Legal and professional fees	1,555,471	1,103,532
Advertisement and promotions	1,216,580	981,195
Bank charges	774,245	801,525
Printing and stationery	480,689	466,667
Government expenses	460,682	502,036
Others	1,219,730	860,927
	69,852,957	69,897,042